1. Home
  2. About FDA
  3. Performance Data
  4. FDA-TRACK: Agency-wide Program Performance
  5. FDA-TRACK: Animal Drug User Fee Act Performance - INAD H Submissions Submitted at Division Level
  1. FDA-TRACK: Agency-wide Program Performance

FDA-TRACK: Animal Drug User Fee Act Performance - INAD H Submissions Submitted at Division Level

Subscribe to FDA-TRACK Updates

On September 30, 2023, the fourth reauthorization of the Animal Drug User Fee Act (ADUFA), referred to as ADUFA V, was signed into law. ADUFA V amends the Federal Food, Drug, and Cosmetic Act (FD&C Act) by reauthorizing ADUFA for an additional five years (FY 2024 through FY 2028). ADUFA provides FDA with revenue to enhance the performance and predictability in review times for the animal drug industry and provides FDA with resources to improve its review of applications for new animal drugs, with the result that safe and effective new products will be more readily available.

Per the ADUFA V goals letter, beginning in FY 2024, FDA will report quarterly in FDA‐TRACK the number of H submissions submitted to each review division in the Office of New Animal Drug Evaluation. H submissions have a 100-day review clock and are submitted under Investigation New Animal Drug files in support of a meeting request, in support of a protocol, or to reach agreement on the raw data to submit in a Target Animal Safety data submission.

FY 2026 YTD includes preliminary performance as of 12/31/2025.

Division CodeCode Description
DBDivision of Biotechnology
DBISMDivision of Business Information Science and Management
DCADDivision of Companion Animal Drugs
DFADDivision of Food Animal Drugs
DHFSDivision of Human Food Safety
DMTDivision of Manufacturing Technologies
DSBSDivision of Statistical & Biological Sciences

 

Download FDA-TRACK: ADUFA - INAD H Submissions Submitted by Division Dataset


Note: The data provided on this website are produced on an ongoing basis for performance management purposes and are subject to change due to updates of preliminary estimates, corrections, or other reasons.

Sign up to receive FDA-TRACK updates

Get regular FDA email updates delivered on this topic to your inbox.
Back to Top